Spidel et al., 2017 - Google Patents
Site-specific conjugation to native and engineered lysines in human immunoglobulins by microbial transglutaminaseSpidel et al., 2017
- Document ID
- 8899645139829462483
- Author
- Spidel J
- Vaessen B
- Albone E
- Cheng X
- Verdi A
- Kline J
- Publication year
- Publication venue
- Bioconjugate Chemistry
External Links
Snippet
The use of microbial transglutaminase (MTG) to produce site-specific antibody–drug conjugates (ADCs) has thus far focused on the transamidation of engineered acyl donor glutamine residues in an antibody based on the hypothesis that the lower specificity of MTG …
- 101700034322 TGAS 0 title abstract description 197
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Spidel et al. | Site-specific conjugation to native and engineered lysines in human immunoglobulins by microbial transglutaminase | |
Strop | Versatility of microbial transglutaminase | |
Smith et al. | Chemoenzymatic Fc glycosylation via engineered aldehyde tags | |
Dickgiesser et al. | Site-specific conjugation of native antibodies using engineered microbial transglutaminases | |
Hofer et al. | Molecularly defined antibody conjugation through a selenocysteine interface | |
CN108602878B (en) | C-terminal lysine conjugated immunoglobulin | |
Agarwal et al. | Site-specific antibody–drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development | |
Boeggeman et al. | Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection | |
Marmelstein et al. | Tyrosinase-mediated oxidative coupling of tyrosine tags on peptides and proteins | |
Lizak et al. | N-Linked glycosylation of antibody fragments in Escherichia coli | |
US20210171998A1 (en) | Lysine conjugated immunoglobulins | |
Vila-Perelló et al. | Streamlined expressed protein ligation using split inteins | |
Debon et al. | Enzymatic bioconjugation: a perspective from the pharmaceutical industry | |
Manabe et al. | Characterization of antibody products obtained through enzymatic and nonenzymatic glycosylation reactions with a glycan oxazoline and preparation of a homogeneous antibody–drug conjugate via Fc N-glycan | |
Teufl et al. | Engineering strategies to overcome the stability–function trade-off in proteins | |
Su et al. | Custom-designed affinity capture LC-MS F (ab′) 2 assay for biotransformation assessment of site-specific antibody drug conjugates | |
Chen et al. | Stabilizing the CH2 domain of an antibody by engineering in an enhanced aromatic sequon | |
Zhang et al. | General and robust chemoenzymatic method for glycan-mediated site-specific labeling and conjugation of antibodies: facile synthesis of homogeneous antibody–drug conjugates | |
Grunewald et al. | Efficient preparation of site-specific antibody–drug conjugates using phosphopantetheinyl transferases | |
Hui et al. | Optimization of photoactive protein Z for fast and efficient site-specific conjugation of native IgG | |
Pirzer et al. | Generation of potent anti-HER1/2 immunotoxins by protein ligation using split inteins | |
Hwang et al. | Site-specific lysine Arylation as an alternative bioconjugation strategy for chemically programmed antibodies and antibody–drug conjugates | |
Kotapati et al. | Universal affinity capture liquid chromatography-mass spectrometry assay for evaluation of biotransformation of site-specific antibody drug conjugates in preclinical studies | |
Ou et al. | One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody–Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling | |
Le Gall et al. | Dual site-specific chemoenzymatic antibody fragment conjugation using CRISPR-based hybridoma engineering |